International Journal of Cancer: 20-Year Post-Hoc Analysis Confirms 49% Overall Survival After Multipeptide Melanoma Vaccination in Resected Stage IIB-IV Disease
A post-hoc analysis in the International Journal of Cancer tracked 51 patients from the Mel39 randomized phase II trial of multipeptide vaccination for resected high-risk melanoma. At median follow-up of 16.1 years (21.2 years for surviving participants), the 12-peptide vaccine arm reported 65% 10-year and 49% 20-year overall survival vs. the 4-peptide arm (HR 0.64, 95% CI 0.29–1.40). The 20-year dataset represents among the longest published follow-up for any cancer peptide vaccine and reinforces that antigen breadth drives durability; sex-specific differences were documented, with females showing improved recurrence-free survival.